This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Asiimwe D, Mauti GO, Kiconco R. Prevalence and risk factors associated with type 2 diabetes in elderly patients aged 45–80 years in Kanungu district. J Diabetes Res. 2020; 2020: 5152146.AsiimweDMautiGOKiconcoRPrevalence and risk factors associated with type 2 diabetes in elderly patients aged 45–80 years in Kanungu districtJ Diabetes Res20202020515214610.1155/2020/5152146Search in Google Scholar
American Diabetes Association (ADA), “Classification and diagnosis of diabetes: standards of medical care in diabetes,” Diabetes Care. 2019; 42, (5): 13–28.American Diabetes Association (ADA)“Classification and diagnosis of diabetes: standards of medical care in diabetes,”Diabetes Care2019425132810.2337/dc19-S002Search in Google Scholar
World Health Organization (WHO). Classification of diabetes mellitus. WHO. 2019; pp8.World Health Organization (WHO)Classification of diabetes mellitusWHO20198Search in Google Scholar
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Diabetes Res Clin Pract. 2019. 2019: 107843.SaeediPPetersohnISalpeaPMalandaBKarurangaSUnwinNGlobal and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045Diabetes Res Clin Pract2019201910784310.1016/j.diabres.2019.10784331518657Search in Google Scholar
Liu, YC., Nguyen, PA., Humayun, A., Chien, SC., Yang, HC.et al.). Does long-term use of antidiabetic drugs changes cancer risk? Medicine, 2019; 98(40), e17461.LiuYC.NguyenPA.HumayunA.ChienSC.YangHCDoes long-term use of antidiabetic drugs changes cancer risk?Medicine20199840e1746110.1097/MD.0000000000017461678324431577776Search in Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer. 2019; 69(1): 7–34.SiegelRLMillerKDJemalACancer statistics, 2019Cancer201969173410.3322/caac.2155130620402Search in Google Scholar
Abudawood M. Diabetes and cacer- a comprehensive review. J Res Med Sci. 2019; 24:94.AbudawoodMDiabetes and cacer- a comprehensive reviewJ Res Med Sci.2019249410.4103/jrms.JRMS_242_19685654431741666Search in Google Scholar
Bailey CJ. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. Clin Pharmacol Ther. 2015;98(2):170–184.BaileyCJThe Current Drug Treatment Landscape for Diabetes and Perspectives for the FutureClin Pharmacol Ther201598217018410.1002/cpt.14425963904Search in Google Scholar
Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care. 2014; 37(4):985–92TurnerLWNarteyDStaffordRSSinghSAlexanderGCAmbulatory treatment of type 2 diabetes in the U.S., 1997–2012Diabetes Care20143749859210.2337/dc13-2097417832524198301Search in Google Scholar
Steven H, Barag DO. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long term patient adherence. J Am Osteopath Assoc. 2011; 111: S3–S11.StevenHBaragDOInsulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long term patient adherenceJ Am Osteopath Assoc.2011111S3S11Search in Google Scholar
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12(3): 159–169.PollakMThe insulin and insulin-like growth factor receptor family in neoplasia: an updateNat Rev Cancer201212315916910.1038/nrc321522337149Search in Google Scholar
Mannucci E. Insulin therapy and cancer in type 2 diabetes. Int Sch Ret Notices. 2012; 2012: 240634.MannucciEInsulin therapy and cancer in type 2 diabetesInt Sch Ret Notices2012201224063410.5402/2012/240634350437123209929Search in Google Scholar
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocrine-Related Cancer. 2009; 16(4): 1103–1123.VigneriPFrascaFSciaccaLPandiniGVigneriRDiabetes and cancerEndocrine-Related Cancer20091641103112310.1677/ERC-09-008719620249Search in Google Scholar
Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127(4): 1044–1050.YangYXHennessySLewisJDInsulin therapy and colorectal cancer risk among type 2 diabetes mellitus patientsGastroenterology200412741044105010.1053/j.gastro.2004.07.01115480982Search in Google Scholar
Jonasson JM, Ljung R, Talbäck M, Haglund N, Gudbjörnsdòttir S, Steineck J. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia,. 2009; 52(9): 1745–1754.JonassonJMLjungRTalbäckMHaglundNGudbjörnsdòttirSSteineckJInsulin glargine use and short-term incidence of malignancies-a population-based follow-up study in SwedenDiabetologia20095291745175410.1007/s00125-009-1444-219588120Search in Google Scholar
Yang X, Ko GTC, So W. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010; 59(5): 1254–1260.YangXKoGTCSoWAssociations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registryDiabetes20105951254126010.2337/db09-1371285790620185812Search in Google Scholar
ORIGIN Trial Investigators, Gerstein HC, Bosch J. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine. 2012; 367(4): 319–328.ORIGIN Trial InvestigatorsGersteinHCBoschJBasal insulin and cardiovascular and other outcomes in dysglycemiaThe New England Journal of Medicine2012367431932810.1056/NEJMoa120385822686416Search in Google Scholar
Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Hormone and Metabolic Research. 2007; 39(1): 65–67.StaigerKHennigeAMStaigerHHäringHUKellererMComparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cellsHormone and Metabolic Research2007391656710.1055/s-2007-95735217226117Search in Google Scholar
Morden NE, Liu SK, Smith J, Mackenzie TM, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011; 34(9): 1965–1971MordenNELiuSKSmithJMackenzieTMSkinnerJKorcMFurther exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patientsDiabetes Care20113491965197110.2337/dc11-0699316126321775752Search in Google Scholar
Wang GS, Hoyte C. Review of biguanides (metformin) toxicity. J Intensive Care Med. 2018; 34(11): 1177.WangGSHoyteCReview of biguanides (metformin) toxicityJ Intensive Care Med20183411117710.1177/088506661879338530126348Search in Google Scholar
American Diabetes Association. Prevention or delay of type 2 diabetes: standards of medical care in diabetes. Diabetes Care. 2019; 42 (Suppl.1): 529–533.American Diabetes AssociationPrevention or delay of type 2 diabetes: standards of medical care in diabetesDiabetes Care201942Suppl.1529533Search in Google Scholar
Hotta N. A new perspective on the biguanides, metformin therapy in type 2 diabetes and lactic acidosis. J Diabetes Investig. 2019; 10(4): 906–908.HottaNA new perspective on the biguanides, metformin therapy in type 2 diabetes and lactic acidosisJ Diabetes Investig201910490690810.1111/jdi.13090662696031152685Search in Google Scholar
Hawley SA, Ross FA, Chevtzoff C. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010; 11:554–65.HawleySARossFAChevtzoffCUse of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activationCell Metab2010115546510.1016/j.cmet.2010.04.001293596520519126Search in Google Scholar
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res. 2010; 3(9): 1158.PollakMMetformin and other biguanides in oncology: advancing the research agendaCancer Prev Res.201039115810.1158/1940-6207.CAPR-10-0175295441220810670Search in Google Scholar
Algire C, Zakikhani M, Blouin M-J, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr Relat Cancer. 2008; 15:833–839.AlgireCZakikhaniMBlouinM-JShuaiJHPollakMMetformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growthEndocr Relat Cancer.20081583383910.1677/ERC-08-003818469156Search in Google Scholar
Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, Meier CR. Long term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33:1304–8.BodmerMMeierCKrahenbuhlSJickSSMeierCRMeierCRLong term metformin use is associated with decreased risk of breast cancerDiabetes Care2010331304810.2337/dc09-1791287544420299480Search in Google Scholar
Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011; 2: 98.MulthoffGMollsMRadonsJChronic inflammation in cancer developmentFront Immunol201129810.3389/fimmu.2011.00098334234822566887Search in Google Scholar
Polak M. Potential application of biguanides in oncology. J Clin Invest. 2013; 2013: 167232.PolakMPotential application of biguanides in oncologyJ Clin Invest2013201316723210.1172/JCI67232375425023999444Search in Google Scholar
Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18(11):1272–1282.ZongWXDitsworthDBauerDEWangZQThompsonCBAlkylating DNA damage stimulates a regulated form of necrotic cell deathGenes Dev.200418111272128210.1101/gad.119990442035315145826Search in Google Scholar
Bonanni B. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593–2600.BonanniBDual effect of metformin on breast cancer proliferation in a randomized presurgical trialJ Clin Oncol.201230212593260010.1200/JCO.2011.39.376922564993Search in Google Scholar
Hosono K. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 2010;3(9):1077–1083.HosonoKMetformin suppresses colorectal aberrant crypt foci in a short-term clinical trialCancer Prev Res.2010391077108310.1158/1940-6207.CAPR-10-018620810669Search in Google Scholar
Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012;2(4):344–355.MartinMJHaywardRVirosAMaraisRMetformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-ACancer Discov.20122434435510.1158/2159-8290.CD-11-0280336471022576211Search in Google Scholar
Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia. 2012; 55 (8): 2096–2108SeinoSCell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylureaDiabetologia20125582096210810.1007/s00125-012-2562-922555472Search in Google Scholar
Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002; 51 (Suppl 3): S368–376.ProksPReimannFGreenNGribbleFAshcroftFSulfonylurea stimulation of insulin secretionDiabetes200251Suppl 3S36837610.2337/diabetes.51.2007.S36812475777Search in Google Scholar
Núñez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E et al. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol. 2013; 14(1):6NúñezMMedinaVCriccoGCrociMCoccaCRiveraEGlibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231BMC Pharmacol Toxicol2013141610.1186/2050-6511-14-6355838623311706Search in Google Scholar
Ardehali H, O’Rourke B. Mitochondrial K(ATP) channels in cell survival and death. J Mol Cell Cardiol. 2005; 39(1):7–16ArdehaliHO’RourkeBMitochondrial K(ATP) channels in cell survival and deathJ Mol Cell Cardiol200539171610.1016/j.yjmcc.2004.12.003269253415978901Search in Google Scholar
Qian X, Li J, Ding J, Wang Z, Duan L, Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol. 2008; 76(12):1705–15QianXLiJDingJWangZDuanLHuGGlibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803Biochem Pharmacol2008761217051510.1016/j.bcp.2008.09.00918840412Search in Google Scholar
Pasello G, Urso L, Conte P, Favarreto. Effects of sulphonylureas on tumor growth: a eview of the literature. Oncologist. 2013; 18(10):118–1125.PaselloGUrsoLContePFavarretoEffects of sulphonylureas on tumor growth: a eview of the literatureOncologist20131810118112510.1634/theoncologist.2013-0177380515424043597Search in Google Scholar
Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci. 2007; 20(2):160–3.PanHZChangDFengLGXuFJKuangHYLuMJOxidative damage to DNA and its relationship with diabetic complicationsBiomed Environ Sci20072021603Search in Google Scholar
Sliwinska A, Sliwinski T, Kasznicki J, Drzewoski J. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol. 2010; 61(3):347–53.SliwinskaASliwinskiTKasznickiJDrzewoskiJEffect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cellsJ Physiol Pharmacol.201061334753Search in Google Scholar
Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A et al. Thiazolidiediones inhibit the growth and invasiveness of adrenocortical cancer cell line H295R. J Clin Endocrinol Metab. 2005; 19(3): 1332–1339.FerruzziPCeniETarocchiMGrapponeCMilaniSGalliAThiazolidiediones inhibit the growth and invasiveness of adrenocortical cancer cell line H295RJ Clin Endocrinol Metab.20051931332133910.1210/jc.2004-097815585569Search in Google Scholar
Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther. 2008; 6(A): 25–34.BlanquicettCRomanJHartCMThiazolidinediones as anti-cancer agentsCancer Ther20086A2534Search in Google Scholar
Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R et al. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia. 2006; 8(10):851–61.VignatiSAlbertiniVRinaldiAKweeIRivaCOldriniRCellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cellsNeoplasia20068108516110.1593/neo.06433171592417032502Search in Google Scholar
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999; 20(10):1905–11ClayCENamenAMAtsumiGWillinghamMCHighKPKuteTEInfluence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cellsCarcinogenesis1999201019051110.1093/carcin/20.10.190510506103Search in Google Scholar
Yang B, Lin P, Carrick KM, McNulty JA, Clifton LG, Winegar DA et al. PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun. 2005; 334(1):176–82YangBLinPCarrickKMMcNultyJACliftonLGWinegarDAPPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF ratsBiochem Biophys Res Commun200533411768210.1016/j.bbrc.2005.06.07815993383Search in Google Scholar
Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancers: reults of a meta-analysis of randomized clinical trials. Acta Diabetol. 2014; 51(1): 91–101.MonamiMDicembriniIMannucciEThiazolidinediones and cancers: reults of a meta-analysis of randomized clinical trialsActa Diabetol20145119110110.1007/s00592-013-0504-823851465Search in Google Scholar
Lewis J. D., Ferrara A., Peng T. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34 (4): 916–922.LewisJ. D.FerraraA.PengT.Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort studyDiabetes Care201134491692210.2337/dc10-1068306405121447663Search in Google Scholar
Hsiao F.-Y., Hsieh P.-H., Huang W.-F., Tsai Y.-W., Gau C.-S. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A Nested Case-control Study. Drug Safety. 2013; 36(8):b643–649.HsiaoF.-Y.HsiehP.-H.HuangW.-F.TsaiY.-W.GauC.-SRisk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A Nested Case-control StudyDrug Safety2013368b64364910.1007/s40264-013-0080-4Search in Google Scholar
Chiu M, McBeth L, Sindhwani P, Hinds TD. Deciphering the roles of thiazolidinediones and PPARγ in bladder cancer. PPAR Res. 2017; 2017: 4810672.ChiuMMcBethLSindhwaniPHindsTDDeciphering the roles of thiazolidinediones and PPARγ in bladder cancerPPAR Res20172017481067210.1155/2017/4810672Search in Google Scholar
Bellomo DA, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tither glycemic control than glyburide in patients with type 2 diabetes with prevalent postprandial hyperglycemia. Diabet Med, 2011; 28(5): 560–65.BellomoDAStefanelliGLaviolaLGiorginoRGiorginoFNateglinide provides tither glycemic control than glyburide in patients with type 2 diabetes with prevalent postprandial hyperglycemiaDiabet Med20112855606510.1111/j.1464-5491.2010.03219.xSearch in Google Scholar
Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials”. Diabetes Metab. 2006; 32 (2): 113–20BlickléJFMeglitinide analogues: a review of clinical data focused on recent trialsDiabetes Metab20063221132010.1016/S1262-3636(07)70257-4Search in Google Scholar
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97(7):E1170–5.ChangCHLinJWWuLCLaiMSChuangLMOral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitusJ Clin Endocrinol Metab2012977E1170510.1210/jc.2012-116222563104Search in Google Scholar
Li D, Yeung SJ, Hassan MM, Konopleva M, Abruzesse JL. Anti-diabetic therapies affect the risk of pancreatic cancer. Gastroenetrology. 2009; 137(2): 482–488.LiDYeungSJHassanMMKonoplevaMAbruzesseJLAnti-diabetic therapies affect the risk of pancreatic cancerGastroenetrology2009137248248810.1053/j.gastro.2009.04.013273509319375425Search in Google Scholar
McIntosh, C; Demuth, H; Pospisilik, J; Pederson, R (). Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?. Regulatory Peptides. 2005; 128 (2): 159–65.McIntoshCDemuthHPospisilikJPedersonRDipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?Regulatory Peptides200512821596510.1016/j.regpep.2004.06.00115780435Search in Google Scholar
Overbeek JA, Bakker M, van der Heijden AAW, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018; 34(5):e3004OverbeekJABakkerMvan der HeijdenAAWvan Herk-SukelMPPHeringsRMCNijpelsGRisk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysisDiabetes Metab Res Rev2018345e300410.1002/dmrr.300429573125Search in Google Scholar
Urasaki Y, Ohnuma K, Morimoto C, Dang N. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634–1645.UrasakiYOhnumaKMorimotoCDangNThe role of CD26/dipeptidyl peptidase IV in cancerFront Biosci2008131634164510.2741/278717981655Search in Google Scholar
Bishnoi R, Hong Y, Shah C, Azka A, Skelton WP, Huo J. et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Cancer Med. 2019; 8(8): 3918–3927.BishnoiRHongYShahCAzkaASkeltonWPHuoJDipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare studyCancer Med2019883918392710.1002/cam4.2278663918731124302Search in Google Scholar
Hinnen D. Glucagon-like 1 peptides receptor for type 2 diabetes. Diabetes spectrum. 2017; 30(3): 202–210.HinnenDGlucagon-like 1 peptides receptor for type 2 diabetesDiabetes spectrum201730320221010.2337/ds16-0026Search in Google Scholar
Bjerre Knudsen L, Madsen LW, Andersen S. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151 (4): 1473–1486.Bjerre KnudsenLMadsenLWAndersenSGlucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferationEndocrinology201015141473148610.1210/en.2009-1272Search in Google Scholar
Chalmer T, Almdal TP, Vilsbøll T, Knop FP. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. Expert Opinion on Drug Safety. 2015; 14(1): 171–180.ChalmerTAlmdalTPVilsbøllTKnopFPAdverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancerExpert Opinion on Drug Safety201514117118010.1517/14740338.2015.975205Search in Google Scholar
Liu Y, Zhang X, Chao S, Zhao X, Ji L. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. J Diabetes Res. 2019; 2019: 1534365.LiuYZhangXChaoSZhaoXJiLRisk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-AnalysisJ Diabetes Res20192019153436510.1155/2019/1534365Search in Google Scholar
Dicembrini I, Nreu B, Mannucci E, Monami M. Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled Trials. Diabetes Obes Metab 2019; 21(8)1871–1877.DicembriniINreuBMannucciEMonamiMSodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled TrialsDiabetes Obes Metab20192181871187710.1111/dom.13745Search in Google Scholar
Nasiri AI, Rodrigues MI, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab. 2019; 7: 10.NasiriAIRodriguesMILiZLeitnerBPPerryRJSGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemiaCancer Metab.201971010.1186/s40170-019-0203-1Search in Google Scholar
Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Tanaka T et al. SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction. Diabetes. 2018; 67 (Suppl 1): 255KomatsuSNomiyamaTNumataTKawanamiTHamaguchiYTanakaTSGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria DysfunctionDiabetes201867Suppl 125510.2337/db18-255-ORSearch in Google Scholar
Zhao Y, Wang Y, Lou H, Shan L. Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Oncotarget. 2017; 8(46): 81027–81039.ZhaoYWangYLouHShanLAlpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysisOncotarget2017846810278103910.18632/oncotarget.17515Search in Google Scholar
Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1997; 36(3):143–5InoueITakahashiKNojiSAwataTNegishiKKatayamaSAcarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitusDiabetes Res Clin Pract1997363143510.1016/S0168-8227(97)00045-4Search in Google Scholar